Introduction of departments
The breast surgery team of Hiroshima University Hospital consists of 7 medical specialists of breast cancer and 2 medical oncologists. We provide the total oncological care by team medicine. We promote hybrid endoscopy-assisted breast surgery to maintain curability and improve cosmetic outcome. Breast cancer board is regularly held to decide treatment strategy and multidisciplinary treatment is implemented. International and domestic clinical trials have been offered to our institution.
Overview (left) and instruments (right) in hybrid endoscopy-assisted breast surgery.
Treatment outcome of breast cancer
Number of breast cancer surgery
The 5-year and 10-year survivals are as follows; stage 0, 100% and 99%; stage I, 97% and 93%; stage II, 94% and 88%; stage III, 83% and 72%, respectively.
We proceed with development and clinical application of new modalities of breast imaging; portable microwave breast tumor detector and ring-type dedicated breast PET.
Basic research is focusing on the growth pathway of hormone-positive breast cancer and the functional subpopulation of tumor-infiltrating lymphocytes.
Microwave breast imaging (left) and visualization of intratumoral heterogeneity using dedicated breast PET.